Sökning: "childhood acute lymphoblastic leukemia"

Visar resultat 1 - 5 av 33 avhandlingar innehållade orden childhood acute lymphoblastic leukemia.

1. 1. Chemotherapy in Childhood Acute Lymphoblastic Leukemia : In vitro cellular drug resistance and pharmacokinetics

   Författare :Britt-Marie Frost; Henrik Schröder; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Obstetrics and gynaecology; cytotoxicity; drug resistance; pharmacokinetics; Acute lymphoblastic leukemia; childhood; in vitro assay; vincristine; doxorubicin; Down`s syndrome; CHS 828.; Obstetrik och kvinnosjukdomar; Obstetrics and women s diseases; Obstetrik och kvinnosjukdomar; pediatrik; Pediatrics;

   Sammanfattning : The aims of the studies described in this thesis were to investigate the pharmacokinetics of and cellular resistance to chemotherapy as causes of treatment failure in childhood acute lymphoblastic leukemia (ALL).Leukemic cells from 370 children with newly diagnosed ALL were tested by the Fluorometric Microculture Cytotoxicity Assay to measure their resistance to each of ten standard cytotoxic drugs. LÄS MER

3. 2. Optimizing Chemotherapy in Childhood Acute Myeloid Leukemia

   Författare :Josefine Palle; Gudmar Lönnerholm; Britt-Marie Frost; Rolf Larsson; Henrik Schröder; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; childhood; acute myeloid leukemia; drug resistance; pharmacokinetics; chromosomal abnormalities; Down syndrome; MLL-rearrangement; t 9; 11 ; Paediatric medicine; Pediatrisk medicin;

   Sammanfattning : Despite major advances in our understanding of the biology of childhood acute myeloid leukemia (AML) and the development of new cytotoxic drugs, the prognosis of long-term survival is still only 60-65 %.In the present research, we studied the pharmacokinetics of drugs used in the induction therapy of childhood AML and performed in vitro drug sensitivity testing of leukemic cells from children with AML. LÄS MER

4. 3. Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia

   Författare :Ingrid Thörn; Christer Sundström; Richard Rosenquist; Gisela Barbany; Johan Botling; Kjeld Schmiegelow; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Childhood acute lymphoblastic leukemia; minimal residual disease; IG TCR gene rearrangements; BCR-ABL1 fusion gene transcripts; real-time quantitative PCR; multicolor flow cytometry; Pathology; Patologi; Pathology; patologi;

   Sammanfattning : Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy of bone marrow (BM) smears, but due to more effective therapies more sensitive methods are needed. Today, detection of minimal residual disease (MRD) using immunological and molecular techniques can be 100 times more sensitive than morphology. LÄS MER

5. 4. Molecular Genetic Characterization of Acute Lymphoblastic Leukemia with a Poor Prognosis

   Författare :Setareh Safavi; Avdelningen för klinisk genetik; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Acute lymphoblastic leukemia; hypodiploidy; adult acute lymphoblastic leukemia;

   Sammanfattning : Acute lymphoblastic leukemia (ALL) affects individuals at all ages, with peak incidences in children 50 years. ALL is broadly categorized into B-cell precursor (BCP) and T-cell ALL with specific clinical features associated with outcome. LÄS MER

7. 5. Vascular density and bone marrow fibrosis in childhood acute lymphoblastic leukemia

   Författare :Ulrika Norén Nyström; Anders Bergh; Erik Forestier; Göran Roos; Henrik Schrøder; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Childhood acute lymphoblastic leukemia; microvessel density; bone marrow fibrosis; in vitro drug resistance; minimal residual disease; outcome; Oncology; Onkologi;

   Sammanfattning : Background: In childhood acute lymphoblastic leukemia (ALL), the cure rate has now reached 80% in the western world. Even so, 15¬–20% will die from the disease or treatment-related causes, among them children who did not present any known unfavorable features at diagnosis. LÄS MER